[Press release] Oncodesign records positive profitability for the second straight year and doubles its operating profit within the context of the global health crisis

08/04/2021

DOWNLOAD

[Congress] Bio Spring Europe, March 22-25, 2021

[Congress] Bio Spring Europe, March 22-25,2021

Oncodesign BU Services  and Oncodesign BU Biotech will be present at BIO SPRING Europe 2021. Find your innovative & scientific solution provider or partner!

  • •Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology, Infectious Diseases (Covid-19) and Inflammatory Diseases.
  • •Oncodesign BU Biotech is a clinical-stage drug discovery Business Unit that capitalizes on its next-generation kinase inhibitor technology called Nanocyclix® consisting of highly potent and selective small macrocycles to tackle novel and untractable kinases of interest.

Oncodesign Service - DRIVE-IDDS™  premium & integrated offering from Hit Findings to IND filing

This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases. 

DRIVE-SM

DRIVE-SM is our integrated discovery engine for small molecule discovery and development - from Hit Finding to IND filing - in oncology and inflammatory diseases. Access to our multiple innovative hit-finding solutions, computational and medicinal chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology and pharmaco-imaging expertise and capabilities all in one-stop shop.

Set up your appointment with Emily Fang

DRIVE STRT

DRIVE-STRT is our new platform to enable the generation of novel systemic targeted radiotherapeutics in clinical oncology.

Oncodesign and its strategic partners are applying their expertise in the rationalization, in the design, and in the optimization of targeted radiopharmaceutical agents effective against specific cancers, with demonstration of preclinical proof of concept and safety margins, from the preclinical to the early clinical stages of your project. 

Set up your appointment with Cyril Berthet

Oncodesign Biotech - Value creation through innovative technology Nanocyclix®

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both unexplored and intractable kinases in a powerful and targeted manner. The approach is "Probe based" rather than "Target based", meaning that potent and selective kinase inhibitor "Probes" are directly generated using the macrocyclic chemistry platform. These probes allow to identify accessible kinases using  a broad profiling approach and are used for early cellular Proof of Concept of the kinase(s) of interest in specific disease indications.

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with strong potential to treat diseases with high unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development (a PET tracer for a specific type of lung cancer) and molecules at an earlier stage of development.

Recent successes include strong advancement on LRRK2 inhibitors for Parkinson disease - a notoriously difficult kinase (in partnership with Servier), and the selection of a first in class candidate drug against the novel kinase RIPK2, a promising target in immuno-inflammation and auto-immune diseases. The latter is subject to ongoing partnering discussions and is advancing on its route towards IND in 2021

Set up your appointment with Jan Hoflack

[Press release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis

28/01/2021

[Congress] Microbiota & Health Day - 26 January, 2021

[Congress] Microbiota & Health Day - 26 January, 2021

Tailor-made strategies to your needs for the investigation of the efficacy of your bacteria-based treatments and/or the effect of your therapies on microbiota. 

Join Dr. Sylvie Maubant and Emilie Soulier to discover how Oncodesign assess the interplay between tumor or inflammatory disease of interest (e.g. colitis), microbiota and therapies.

Our comprehensive platform dedicated to microorganisms helps you to investigate in vitro and/or in vivo the bacteria as immuno-modulating vectors or agents.

Our teams have developed models for pathologies related to microbiota disorders and therefore can customize studies for programs from preclinical to early clinical phases.

We guide you on all projects on bacteria-based therapies or any treatment acting on microbiota across different therapeutic areas i.e. oncology and inflammatory diseases.

I contact Sylvie & Emilie!

I know to know more!